---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016647"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:04:48.571855+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q2 2022 net loss $26.5M; IND submitted for MRT-2359

## Summary
- Net loss of $26.5M for Q2 2022, compared to $18.4M in Q2 2021.
- Cash, equivalents, and marketable securities of $299.5M as of June 30, 2022; expected runway into late 2024.
- R&D expenses of $20.9M in Q2 2022 vs $14.6M in Q2 2021, driven by MRT-2359 advancement and platform expansion.
- Submitted IND for MRT-2359 (GSPT1 degrader) for Myc-driven solid tumors; Phase 1/2 trial planned for Q4 2022.
- Progress on CDK2 and NEK7 programs toward development candidate nominations.

## SEC filing metadata
- accession: 0000950170-22-016647
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017022016647/0000950170-22-016647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017022016647/glue-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016647
- JSON: https://secwatch.observer/filing/0000950170-22-016647.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.